In recent years, nonalcoholic fatty liver disease has gradually become the main factor of liver-related mortality in China. The pathogenesis of nonalcoholic fatty liver disease mainly associates with the metabolic syndrome and its risk factors include obesity, type 2 diabetes, abnormal lipid metabolism, etc. These risk factors are closely related to the cardiovascular disease. Therefore, the cardiovascular mortality has become a primary cause of death in nonalcoholic fatty liver disease. Statins are the main lipid-lowering drugs. There is evidence that nonalcoholic fatty liver disease patients using statins not only can effectively reduce the liver transaminase level and the mortality of cardiovascular disease, but also can effectively improve hepatic steatosis, and may delay progression of liver fibrosis.